Curcumin decreases specificity protein expression in bladder cancer cells

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5345-5354

  Chadalapaka, Gayathri ^a   Jutooru, Indira ^a   Chintharlapalli, Sudhakar ^b   Papineni, Sabitha ^b   Smith III, Roger ^a   Li, Xiangrong ^a   Safe, Stephen ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEIN; PROTEIN BCL 2; RNA; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; ANTINEOPLASTIC AGENT; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP;

ANIMAL CELL; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GENE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH; XENOGRAFT; ANIMAL; CELL CULTURE; CELL CYCLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TIME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; RNA, SMALL INTERFERING; SP TRANSCRIPTION FACTORS; TIME FACTORS; TUMOR BURDEN; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 48549085442     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6805     Document Type: Article

References (46)

1. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005;4:206-20.
2. Butler MS. The role of natural product chemistry in drug discovery. J Nat Prod 2004;67:2141-53.
3. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005;41:1955-68.
4. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421.
5. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98.
6. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
7. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo) 1991;110:559-65.
8. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894-900.
9. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-54.
10. Dhillon N, Wolff RA, Abbruzzese JL. Phase II clinical trial of curcumin in patients with advanced pancreatic cancer [abstract]. J Clin Oncol 2006;24:14151.
11. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkBa kinase and Akt activation. Mol Pharmacol 2006;69:195-206.
12. Mohan R, Sivak J, Ashton P, et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000;275:10405-12.
13. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kB and IkB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004;101:2351-62.
14. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31.
15. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 2002;23:143-50.
16. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kB-regulated gene products. Cancer Res 2007;67:3853-61.
17. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in IFN-α-sensitive and IFN-α-resistant human bladder cancer cells. Mol Cancer Ther 2007;6:1022-30.
18. Pae HO, Jeong SO, Jeong GS, et al. Curcumin induces pro-apoptotic endoplasmic reticulum stress in human leukemia HL-60 cells. Biochem Biophys Res Commun 2007;353:1040-5.
19. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1996;1317:95-100.
20. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-κB, and p53. Clin Immunol 1999;93:152-61.
21. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005;11:7490-8.
22. Liu Y, Chang RL, Cui XX, Newmark HL, Conney AH. Synergistic effects of curcumin on all-trans retinoic acid- and 1 α,25-dihydroxyvitamin D3-induced differentiation in human promyelocytic leukemia HL-60 cells. Oncol Res 1997;9:19-29.
23. Alakurtti S, Makela T, Koskimies S, Yli-Kauhaluoma J. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharmacol Sci 2006;29:1-13.
24. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007;67:2816-23.
25. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006;98:855-68.
26. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 (VEGFR1) expression by specificity proteins 1, 3 and 4 in pancreatic cancer cells. Cancer Res 2007;67:3286-94.
27. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 2006;345:292-301.
28. Abdelrahim M, Smith R III, Burghardt R, Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004;64:6740-9.
29. Abdelrahim M, Samudio I, Smith R, Burghardt R, Safe S. Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 2002;277:28815-22.
30. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005;41:2438-48.
31. Nicolas M, Noe V, Jensen KB, Ciudad CJ. Cloning and characterization of the 5′-flanking region of the human transcription factor Sp1 gene. J Biol Chem 2001;276:22126-32.
32. Tapias A, Monasterio P, Ciudad CJ, Noe V. Characterization of the 5′-flanking region of the human transcription factor Sp3 gene. Biochim Biophys Acta 2005;1730:126-36.
33. Khan S, Wu F, Liu S, Wu Q, Safe S. Role of specificity protein (Sp) transcription factors in estrogen-induced gene expression in MCF-7 breast cancer cells. J Mol Endocrinol 2007;39:289-304.
34. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr. NF-kB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-99.
35. Ma Q, Li X, Vale-Cruz D, Brown ML, Beier F, LuValle P. Activating transcription factor 2 controls Bcl-2 promoter activity in growth plate chondrocytes. J Cell Biochem 2007;101:477-87.
36. Yurochko AD, Mayo MW, Poma EE, Baldwin AS, Jr., Huang ES. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kB promoters. J Virol 1997;71:4638-48.
37. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344 Pt 2:305-11.
38. Li Y, Xie M, Yang J, et al. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 2006;25:3296-306.
39. Wu J, Ling X, Pan D, et al. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem 2005;280:9745-51.
40. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997;15:669-76.
41. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998;4:376-83.
42. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
43. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
44. 2+ depletion and cytochrome c release. Biochem Biophys Res Commun 2003;303:1073-9.
45. Gu L, Findley HW, Zhou M. MDM2 induces NF-kB/ p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 2002;99:3367-75.
46. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008;7:464-73.